Hypotension

Hypotension refers to abnormally low blood pressure, a physiological state where the force of blood against artery walls is lower than typically considered healthy. While specific thresholds can vary, it is generally defined by a systolic blood pressure (SBP) below 90 mmHg or a diastolic blood pressure (DBP) below 60 mmHg. Unlike hypertension (high blood pressure), which is often asymptomatic, hypotension frequently presents with noticeable symptoms due to insufficient blood flow to vital organs.

Biological Basis

Blood pressure is a tightly regulated physiological parameter, maintained by complex interactions between the heart’s pumping action, the resistance of blood vessels, and the total blood volume. Neural and hormonal systems, such as the renin-angiotensin-aldosterone pathway, play critical roles in this regulation. Genetic factors are known to influence blood pressure variability and can predispose individuals to both high and low blood pressure. Research indicates that common genetic variants in genes underlying monogenic hypertension can also influence blood pressure in the general population, including aspects related to hypotension.^[1]For instance, specific genetic polymorphisms in genes like leucine rich repeat transmembrane neuronal 4 (LRRTM4) and proprotein convertase subtilisin/kexin type 5 (PCSK5), as well as an intergenic single nucleotide polymorphism (SNP)rs117129097 , have been investigated for their associations with hypotension or their interactive effects with hypotension on cognitive function.^[2]

Clinical Relevance

The clinical manifestations of hypotension can range from mild and transient symptoms to severe, life-threatening conditions. Common symptoms include dizziness, lightheadedness, fainting (syncope), blurred vision, fatigue, and nausea, often exacerbated by standing up quickly (orthostatic hypotension). While mild hypotension may not always require intervention, persistent or symptomatic low blood pressure can significantly impact daily life and lead to complications such as falls, particularly in older adults. Furthermore, studies have explored the link between hypotension and cognitive impairment (CI), especially in aging populations. For example, specific genetic variants inLRRTM4, such as rs13388459 , have been found to interact with hypotension, leading to a higher incidence of CI in hypotensive subjects carrying certain alleles.^[2]Certain demographics, such as individuals of female sex and those with a lower Body Mass Index (BMI), have also been observed to be more prone to hypotension.^[2]

Social Importance

Hypotension carries significant social importance due to its potential to reduce quality of life, particularly among the elderly. The symptoms, such as dizziness and fainting, can lead to increased risks of falls and injuries, impacting independence and requiring greater healthcare support. The association between hypotension and cognitive impairment in aging populations highlights a critical public health concern, as maintaining optimal cognitive function is essential for healthy aging. Understanding the genetic predispositions and clinical implications of hypotension can lead to improved diagnostic strategies, targeted interventions, and better management plans, ultimately enhancing the well-being of affected individuals and reducing the healthcare burden.

Methodological and Statistical Considerations

Research on hypotension-related genetic markers often faces challenges related to sample size, which can limit statistical power to detect modest genetic effects and inflate observed effect sizes. For instance, studies identifying genetic variants for cognitive impairment in hypotensive individuals have noted a relatively small number of cases within the hypotensive group, necessitating replication before establishing these variants as independent risk markers.^[2]Similarly, investigations into blood pressure responses to interventions have identified only a limited number of single nucleotide polymorphisms (SNPs), hindering the development of comprehensive genetic risk scores.^[3]This constraint in sample size and identified variants can lead to an underestimation of the true genetic landscape and may prevent the detection of genuine associations, particularly for traits with complex polygenic architectures.^[4]The generalizability and robustness of genetic findings for hypotension are further limited by the need for independent replication in diverse cohorts. Several studies explicitly call for further replication in different ethnic populations to confirm initial findings, underscoring that results from a single cohort, even with moderate effect sizes, may not be universally applicable.^[2] Furthermore, stringent statistical adjustments, such as Bonferroni correction for multiple testing, while crucial for controlling false positives, can increase the threshold for significance, potentially leading to a failure to detect true associations with smaller effect sizes.^[5] These methodological choices and the absence of broad replication can restrict the confidence in identified genetic markers and their clinical utility.

Phenotypic Characterization and Environmental Factors

Precise phenotypic characterization of hypotension and related outcomes, such as cognitive impairment, presents a significant challenge due to variations in and definition. Studies have noted the lack of detailed blood pressure (BP) variation, continuous BP monitoring, or comprehensive medication lists, which can critically influence the accurate categorization of hypotensive participants.^[2] Similarly, the reliance on single-point assessments or broad diagnostic codes, as well as the use of uniform thresholds without accounting for sex differences in physiological measurements, can introduce misclassification and reduce the accuracy of phenotype assignment.^[6] These imperfections and definitional ambiguities can weaken observed genetic associations and complicate the interpretation of findings by obscuring true biological relationships.

Environmental factors, including medication use and lifestyle, are critical confounders that are often incompletely captured, impacting the interpretation of genetic associations with hypotension. The absence of detailed medication lists prevents precise categorization of participants based on drug use, potentially confounding the observed genetic effects with pharmacological interventions.^[2]Furthermore, short-term dietary interventions may not accurately reflect the long-term impact of diet on blood pressure, limiting the generalizability of findings to chronic physiological responses.^[3]These unmeasured or short-term environmental influences contribute to missing heritability and can obscure the full spectrum of gene-environment interactions, making it difficult to fully understand the complex etiology of hypotension and its sequelae.

Generalizability and Genetic Interpretation

A significant limitation in genetic studies of hypotension is the potential for ancestry bias, which restricts the generalizability of findings across diverse populations. Many genome-wide association studies (GWAS) are predominantly conducted in cohorts of European descent or focus on specific ethnic groups, such as Han Chinese, making it uncertain whether identified genetic associations are transferable to individuals of other ancestries.^[7] While limiting cohorts to similar ancestries can mitigate inflation due to population substructure, it simultaneously reduces the external validity of the results, highlighting the critical need for replication studies in ethnically diverse populations to confirm and extend these genetic insights.^[2]Without such diversity, the full spectrum of genetic contributions to hypotension across global populations remains incompletely understood.

The interpretation of identified genetic variants is often challenged by the fact that many associated single nucleotide polymorphisms (SNPs) are not inherently functional or causal. For example, identified SNPs may be intronic variations or merely physically close to candidate genes, rather than being the direct causal variants influencing pathophysiology.^[2]This limitation means that while associations are established, the precise molecular mechanisms by which these genetic loci contribute to hypotension or related conditions, such as cognitive impairment, remain largely unknown. Future research, including targeted deep sequencing and functional assays, is essential to pinpoint rare or low-frequency functional variants and to elucidate the biological pathways underlying these genetic associations.^[3]

Variants

Genetic variations play a crucial role in shaping an individual’s susceptibility to various physiological conditions, including hypotension. The genes and variants discussed here influence fundamental cellular processes, from calcium handling and metabolism to immune responses and gene expression, all of which can indirectly or directly impact blood pressure regulation. Understanding these genetic underpinnings provides insight into the complex mechanisms contributing to blood pressure variability within the population.

Variants within genes involved in calcium signaling and muscle function, such as_RYR2_ (rs538680895 ), _RYR3_ (rs375764076 ), and _NKAIN2_ (rs191964547 ), are critical in maintaining cardiovascular homeostasis._RYR2_encodes the cardiac ryanodine receptor, a calcium channel essential for calcium release in heart muscle cells, which directly impacts heart contractility and rate, both fundamental determinants of blood pressure. Similarly,_RYR3_contributes to calcium handling in various tissues, potentially including vascular smooth muscle, influencing blood vessel tone. The_NKAIN2_gene, which interacts with the sodium-potassium ATPase pump, is vital for maintaining proper ion gradients across cell membranes, a process essential for the excitability of nerve and muscle cells, including those regulating vascular resistance. Alterations in these genes can lead to dysregulated calcium dynamics or ion balance, thereby affecting cardiac output and vascular tone, potentially contributing to hypotensive states.^[2] Such genetic predispositions underscore the intricate balance required for stable blood pressure, as even subtle changes in these pathways can have systemic effects.^[2] Other variants impact cellular metabolism, growth, and cell surface interactions, with broad implications for systemic health and blood pressure. The _SLC1A5_ gene, linked with _HNRNPMP2_ through rs556322198 , encodes a transporter for neutral amino acids, vital for cellular nutrient uptake and metabolic pathways that support endothelial function and vascular integrity. _FOXO1_ (rs556463174 ) is a transcription factor that regulates genes involved in glucose and lipid metabolism, cell growth, and stress response, all of which are crucial for maintaining healthy blood vessels and systemic metabolic balance. Meanwhile,_MGAT5B_ (rs192072696 ) is involved in N-linked glycosylation, a process that modifies proteins on cell surfaces and affects cell signaling and adhesion, potentially impacting vascular cell interactions and inflammation. _SDC2_ (rs529028826 ) encodes a syndecan protein, important for cell adhesion and signaling, and plays a role in vascular development and repair. Dysregulation in these metabolic and signaling pathways can affect vascular tone, fluid balance, and overall cardiovascular function, contributing to conditions like hypotension . Genetic studies continue to identify novel associations, highlighting the polygenic nature of blood pressure regulation and related traits.^[2] Immune responses, RNA processing, and non-coding RNA elements also contribute to blood pressure regulation through complex mechanisms. The _NLRP1_ gene, associated with _WSCD1_ via rs555697882 , is a key component of the inflammasome, which initiates inflammatory responses. Chronic low-grade inflammation can lead to endothelial dysfunction and affect vascular tone, potentially influencing blood pressure. _HNRNPMP2_, linked with _SLC1A5_, is involved in RNA processing, a fundamental cellular activity that impacts the expression of countless genes, including those relevant to vascular health. _RNASE11_ (rs542904013 ), alongside _OR6S1_, is part of the ribonuclease family, involved in RNA degradation, further influencing gene expression. Additionally, _LINC02196_ (rs530866600 ) represents a long intergenic non-coding RNA, which can regulate gene expression through various mechanisms, thereby influencing cellular processes relevant to vascular function and systemic blood pressure control. Such variants underscore how diverse genetic elements, from protein-coding genes to regulatory RNAs, contribute to the intricate network that maintains blood pressure stability.^[2] Genetic research continually expands our understanding of how these molecular pathways collectively influence complex traits like blood pressure .

Key Variants

RS ID	Gene	Related Traits
rs556322198	SLC1A5 - HNRNPMP2	hypotension
rs556463174	FOXO1	hypotension
rs529028826	SDC2	hypotension
rs542904013	RNASE11 - OR6S1	hypotension
rs191964547	NKAIN2	hypotension
rs375764076	RYR3	hypotension
rs530866600	LINC02196	hypotension
rs538680895	RYR2	hypotension
rs192072696	MGAT5B	hypotension
rs555697882	NLRP1 - WSCD1	hypotension

Definition and Diagnostic Thresholds

Hypotension is precisely defined by specific blood pressure thresholds that indicate abnormally low systemic arterial pressure. Operationally, hypotension is characterized by a Systolic Blood Pressure (SBP) less than 90 mmHg or a Diastolic Blood Pressure (DBP) less than 60 mmHg.^[2] These cut-off values serve as the primary diagnostic criteria in both clinical practice and research settings. For accurate assessment, SBP and DBP values are typically derived from the average of two seated blood pressure measurements taken at rest.^[2]This standardized approach is critical for consistent identification of individuals with hypotension, particularly in studies investigating its broader health implications.

Blood Pressure and Related Terminology

Understanding hypotension requires familiarity with key terms related to blood pressure . Systolic Blood Pressure (SBP) represents the pressure in the arteries when the heart beats, while Diastolic Blood Pressure (DBP) is the pressure in the arteries when the heart rests between beats.^[2] Another important related concept is Mean Arterial Blood Pressure (MAP), which represents the average arterial pressure during a single cardiac cycle.^[8]Furthermore, Pulse Pressure, calculated as the difference between SBP and DBP, provides additional hemodynamic information.^[2] These distinct parameters, obtained through consistent protocols, are fundamental for a comprehensive characterization of an individual’s circulatory status.

Clinical and Research Classifications

While the researchs does not detail specific nosological systems or severity gradations for hypotension, it highlights its classification within a broader clinical and research context. Hypotension can serve as a defining characteristic for specific study populations, such as an aging population being investigated for cognitive impairment.^[2] In such contexts, identifying individuals as hypotensive based on established SBP and DBP thresholds allows researchers to explore associations with other health traits, including genetic polymorphisms like those in LRRTM4 and PCSK5.^[2] This demonstrates a categorical approach to classification, where individuals are grouped as either hypotensive or normotensive for the purpose of genetic and clinical correlation studies.

Clinical Definition and Objective Assessment

Hypotension is clinically defined by specific blood pressure thresholds, typically a systolic blood pressure (SBP) below 90 mmHg or a diastolic blood pressure (DBP) below 60 mmHg.^[2] Objective assessment commonly involves measuring blood pressure after a period of rest, often while seated, with readings taken multiple times to ensure accuracy. For instance, studies have utilized the average of two seated blood pressure measurements at rest, or three morning measurements over several days, obtained by trained observers using standard devices such as mercury or random-zero sphygmomanometers.^[2]These measurements yield quantitative data, including SBP, DBP, and calculated pulse pressure (SBP minus DBP), providing objective indicators for diagnosis.

Average resting SBP in hypotensive individuals has been observed around 108.74 ± 15.97 mmHg, with DBP around 56.42 ± 5.04 mmHg, contrasting with non-hypotensive groups showing SBP of 133.57 ± 19.84 mmHg and DBP of 78.39 ± 11.28 mmHg.^[2] While these numerical values establish the physiological state, the clinical presentation can vary, often correlating with the severity and chronicity of low blood pressure. The time course between blood pressure and other clinical assessments, such as cognitive testing, is often kept within a day to ensure diagnostic relevance.^[2]

Associated Clinical Presentations and Diagnostic Significance

Hypotension is recognized as a significant risk factor for cognitive impairment (CI) and cognitive decline, potentially serving as an early presentation of CI.^[2]Individuals with hypotension exhibit a higher proportion of cognitive impairment; for example, one study noted 33.7% of hypotensive subjects presented with CI compared to 24.0% in non-hypotensive individuals, a statistically suggestive difference even after adjusting for factors like age, sex, education, and smoking.^[2]This clinical correlation highlights the diagnostic value of identifying low blood pressure in populations at risk for neurocognitive disorders. It has been linked to conditions such as Alzheimer’s disease, vascular dementia, and all-cause dementia, emphasizing its role as a prognostic indicator for neurological health.^[2]

Variability and Genetic Influences

The presentation of hypotension exhibits considerable variability among individuals, with certain demographics showing a higher predisposition. For instance, studies indicate that individuals of female sex and those with a lower Body Mass Index (BMI) are particularly prone to developing hypotension.^[2]Beyond demographic factors, genetic variations also play a role in susceptibility; specifically, the single nucleotide polymorphism (SNP)rs117129097 has been associated with an increased likelihood of hypotension.^[2]Furthermore, complex interactions between genetic background and hypotensive status can significantly influence other clinical outcomes, such as cognitive function. For example, hypotensive individuals carrying the T allele ofrs13388459 in the LRRTM4gene show a higher incidence of cognitive impairment compared to those with the C allele, a pattern not observed in non-hypotensive groups.^[2]Similar interactive effects between hypotension and specific alleles inLRRTM4 (rs1075716 , rs62171995 , rs17406146 , rs2077823 , rs62170897 ) and PCSK5 (rs10521467 ) further underscore the phenotypic diversity and genetic heterogeneity underlying its clinical manifestations.^[2]

Causes of Hypotension

Hypotension, characterized by abnormally low blood pressure, arises from a complex interplay of genetic predispositions, environmental factors, and an individual’s physiological state. Understanding these diverse causal pathways is crucial for comprehending the trait.

Genetic Susceptibility

Genetic factors play a role in an individual’s predisposition to hypotension. Research has identified specific genetic variants associated with the trait, highlighting a polygenic influence on blood pressure regulation. For instance, the single nucleotide polymorphism (SNP)rs117129097 , located in an intergenic region near TMEM132C, has been directly linked to hypotension, with individuals carrying certain alleles showing a significantly increased odds ratio for the condition.^[2]While many blood pressure-related genes are often studied in the context of hypertension, common variants in genes underlying both monogenic hypertension and hypotension can collectively influence blood pressure in the general population.^[1] The PCSK5gene, for example, which encodes proprotein convertase subtilisin/kexin type 5, is known to regulate lipid and insulin metabolism and has been associated with blood pressure traits in various studies.^[2]indicating its broader involvement in cardiovascular homeostasis.

Environmental and Lifestyle Factors

Beyond genetic predispositions, various environmental and lifestyle elements significantly contribute to the development of hypotension. Demographic characteristics such as sex and body mass index (BMI) are notable, with studies indicating that female individuals and those with a lower BMI are particularly prone to experiencing hypotension.^[2]Lifestyle choices, including smoking habits, have also been observed to influence an individual’s hypotension status.^[2]Furthermore, dietary factors, such as the intake of sodium and potassium, are well-established determinants of blood pressure regulation, suggesting that specific dietary patterns could contribute to hypotensive states, similar to their known impact on hypertension.^[3]

Gene-Environment Interactions

The manifestation and impact of hypotension can be profoundly shaped by interactions between an individual’s genetic makeup and their environmental exposures. While certain genetic variants might not directly cause hypotension, they can modify an individual’s response to a hypotensive state or influence its downstream effects. For example, specific SNPs within theLRRTM4 gene, as well as the PCSK5 rs10521467 and the intergenic rs117129097 SNPs, have demonstrated suggestive interaction effects with hypotension on the risk of cognitive impairment.^[2]This suggests that genetic predispositions can modulate how the body’s systems, such as cerebral perfusion and synapse organization, respond to low blood pressure, potentially exacerbating adverse outcomes like cognitive decline.^[2] These complex interactions underscore that blood pressure is influenced by a combination of genetic and environmental determinants, rather than either factor in isolation.^[3]

Physiological and Age-Related Determinants

The physiological context and an individual’s age are critical determinants in the occurrence and presentation of hypotension. The condition is frequently observed in aging populations, indicating that age-related changes in cardiovascular regulation, vascular elasticity, or autonomic nervous system function can contribute to lower blood pressure.^[2]Additionally, the use of certain medications can significantly influence blood pressure levels, potentially leading to or exacerbating hypotension as a side effect. While specific medication details were not always comprehensively captured in some studies, their potential to alter blood pressure categorization highlights their importance as a contributing factor.^[2]

Biological Background of Hypotension

Hypotension, characterized by abnormally low blood pressure, represents a disruption in the body’s intricate homeostatic mechanisms designed to maintain adequate perfusion to vital organs. While often asymptomatic, sustained or severe hypotension can lead to significant health consequences, including a heightened risk for cognitive impairment and various forms of dementia, particularly in the aging population.^[2]The biological underpinnings of hypotension involve complex interactions across molecular, cellular, and systemic levels, influenced by genetic predispositions, metabolic pathways, and the coordinated function of multiple organ systems.

Physiological Regulation of Blood Pressure

Maintaining stable blood pressure is a critical physiological function, regulated by a complex interplay of neural, hormonal, and local vascular mechanisms. Key biomolecules and pathways contribute to this balance, including the renin-angiotensin-aldosterone system (RAAS), which controls fluid balance and vasoconstriction through angiotensin II, a potent peptide hormone.^[9] Other important regulators include natriuretic peptides such as those encoded by NPPA and NPPB, which counteract vasoconstriction and promote sodium and water excretion, thereby influencing circulating blood volume.^[10]Disruptions in these regulatory networks, such as altered signaling in vascular smooth muscle cells where angiotensin II antagonizes cGMP signaling, can lead to either elevated or depressed blood pressure.^[4] At the tissue and organ level, the kidneys play a central role in long-term blood pressure control through fluid and electrolyte regulation, with the renal endothelin system also contributing to local vascular tone.^[11] Endothelial function, which involves the production of vasodilators like nitric oxide, is crucial for maintaining vascular health; for instance, the enzyme GTP cyclohydrolase I is vital for endothelial function, and its overexpression can attenuate blood pressure progression in certain hypertensive conditions.^[12]Cellular functions like vascular smooth muscle cell proliferation, partly mediated by pathways involving c-Src and Shc/Grb2/ERK2 in response to angiotensin II, also contribute to the structural integrity and responsiveness of blood vessels, impacting overall systemic blood pressure.^[9]

Genetic Architecture and Molecular Pathways in Hypotension

Genetic mechanisms play a significant role in an individual’s susceptibility to hypotension, influencing the expression and function of key biomolecules involved in blood pressure regulation and metabolism. For instance, common variants in genes likeNPPA and NPPB, which encode natriuretic peptides, are associated with circulating peptide levels and blood pressure.^[10] Genome-wide association studies have begun to identify specific genetic polymorphisms that may modulate blood pressure traits, even if the identified SNPs are often intron variations that might not directly alter protein sequences but could affect gene expression patterns or regulatory networks.^[2] Two genes, LRRTM4 and PCSK5, have been implicated in the context of hypotension-related cognitive impairment.PCSK5(proprotein convertase subtilisin/kexin type 5) encodes an enzyme that processes peptide precursors and regulates numerous molecules, including those involved in lipid and insulin metabolism.^[2] Variations in PCSK5can lead to abnormal high-density lipoprotein metabolism through dysregulation of bile acid signal molecules and influence lipoprotein metabolism by modulating endothelial and lipoprotein lipases, as well as low-density lipoprotein receptor levels via PCSK9 cleavage.^[2]These molecular pathways highlight the interconnectedness of metabolic health with blood pressure regulation, where dyslipidemia, for example, could indirectly impact vascular function and contribute to hypotension.

Cellular Mechanisms and Systemic Consequences of Low Blood Pressure

At the cellular level, specific functions and regulatory networks are vulnerable to the effects of low blood pressure, particularly in sensitive tissues like the brain. LRRTM4(leucine rich repeat transmembrane neuronal 4) is a gene whose genetic polymorphisms, in conjunction with hypotension, have been linked to cognitive impairment.^[2]This suggests that a compromised maintenance of synapse organization, a critical cellular function for neuronal communication, may occur during periods of cerebral hypoperfusion, which is a direct pathophysiological consequence of systemic hypotension.^[2]Such cellular disruptions can impair the brain’s ability to process information and maintain cognitive function.

Systemically, hypotension can lead to widespread consequences due to inadequate blood flow and oxygen delivery to various organs. The brain is particularly susceptible to reduced perfusion, where chronic or recurrent cerebral hypoperfusion can trigger a cascade of events leading to neuronal damage and cognitive decline, manifesting as conditions like Alzheimer’s disease, vascular dementia, and general cognitive impairment.^[2]This systemic consequence underscores how a homeostatic disruption in blood pressure can initiate a pathophysiological process that extends beyond the cardiovascular system, impacting neurological health and highlighting the importance of maintaining optimal blood pressure for overall well-being, particularly in aging populations.

Hormonal and Neurohumoral Control of Vascular Tone

The regulation of blood pressure involves a complex interplay of hormonal and neurohumoral systems that modulate vascular tone and fluid balance. The renin-angiotensin system (RAS) is a primary determinant, critically influencing cardiovascular and renal function. Dysregulation within the RAS, such as diminished angiotensin II (Ang II) production or reduced responsiveness of its receptors, can lead to widespread vasodilation and decreased blood volume, thereby contributing to hypotensive states.^[13] Ang II typically promotes vasoconstriction and actively antagonizes cGMPsignaling in vascular smooth muscle cells, meaning a reduction in its activity shifts the physiological balance towards relaxation of blood vessels.^[4] Conversely, natriuretic peptides, encoded by genes like NPPA and NPPB, act as counter-regulatory hormones, promoting vasodilation and natriuresis (excretion of sodium).^[10] An increase in the activity or sensitivity to these peptides can lead to a reduction in systemic blood pressure through enhanced fluid excretion and generalized vascular relaxation. Furthermore, the renal endothelin system also plays a role in blood pressure regulation.^[11]Insufficient activity of endothelin, a potent vasoconstrictor, could result in inadequate vascular tone and contribute to the development of hypotension.

Endothelial Regulation and Metabolic Pathways

The integrity and function of the endothelium are paramount for maintaining vascular tone, largely through the bioavailability of nitric oxide (NO). GTP cyclohydrolase I (GCH1) is the rate-limiting enzyme in the biosynthesis of tetrahydrobiopterin (BH4), an essential cofactor for endothelial nitric oxide synthase (eNOS).^[12] Studies have shown that overexpression of GCH1 can restore vascular BH4 levels and improve endothelial function, suggesting that deficits in GCH1 activity or BH4 availability could lead to reduced NO production.^[12] This reduction in NO would diminish its vasodilatory effects, potentially contributing to hypotensive conditions if not adequately compensated.

Beyond NO, systemic metabolic processes and oxidative stress can significantly impact vascular function.^[14]While oxidative stress is often associated with conditions of elevated blood pressure, specific patterns of oxidative imbalance or its interactions with other metabolic pathways could influence NO bioavailability or alter vascular smooth muscle cell reactivity in ways that contribute to decreased vascular tone and hypotension. Metabolic regulation and flux control within the endothelium are thus critical for the appropriate production of vasoactive substances.

Intracellular Signaling and Vascular Remodeling

Intracellular signaling cascades within vascular smooth muscle cells (VSMCs) are crucial for maintaining vascular structure and function. Angiotensin II-dependent pathways, involving the activation ofc-Src and the Shc/Grb2/ERK2 signaling cascade, are integral to VSMC proliferation and overall functionality.^[9]A decrease in these proliferative signals or an alteration in VSMC phenotype could compromise the structural integrity and responsiveness of the vascular wall, leading to reduced peripheral resistance and contributing to hypotension.

Regulation of smooth muscle cell differentiation is also mediated by specific transcription factors, such asMrf2alpha and Mrf2beta.^[15] Perturbations in the activity or expression of these transcription factors can lead to abnormal VSMC phenotypes, thereby impacting vascular structure and its ability to maintain adequate blood pressure. Genetic factors, such as mutations in TBX5, are also known to affect cardiovascular development and function, highlighting the importance of genetic regulation in vascular health.^[16] These regulatory mechanisms ensure proper protein modification and post-translational control, which are vital for vascular cellular responses.

Systems-Level Integration and Genetic Influences

Blood pressure regulation is an emergent property of highly integrated physiological networks, where multiple pathways interact and exert hierarchical control. Significant crosstalk exists between signaling pathways, such as the antagonism between Ang II and cGMP signaling in VSMCs, which provides a critical feedback loop for fine-tuning vascular tone.^[4] Disruptions in these intricate interactions, for example, an overactive cGMP pathway or a diminished Ang II influence, can lead to sustained vasodilation and contribute to hypotensive states.

Genetic factors play a substantial role in predisposing individuals to variations in blood pressure. Genome-wide association studies (GWAS) have identified numerous genetic loci and common variants associated with blood pressure regulation, including those within NPPA and NPPB.^[10]These findings underscore the polygenic nature of blood pressure control and suggest that genetic context-dependent effects can influence an individual’s susceptibility to conditions like hypotension.^[17]Understanding these genetic predispositions offers insights into personalized risk assessment and potential therapeutic targets. Beyond direct vascular mechanisms, systemic processes like cytokine signaling can impact blood pressure, as observed inLnk-deficient mice where hematopoietic homeostasis is disrupted.^[18]Such systemic inflammation can contribute to vasodilation and hypotension, further illustrating the complex network interactions that govern blood pressure.

Prognostic and Comorbid Implications of Hypotension

Hypotension, clinically defined as a systolic blood pressure (SBP) below 90 mmHg or a diastolic blood pressure (DBP) below 60 mmHg, holds significant prognostic value, particularly within aging populations. Studies indicate a strong association between hypotension and an increased risk of cognitive impairment (CI), encompassing conditions such as Alzheimer’s disease, vascular dementia, and all-cause dementia.^[2]Research suggests that a decline in blood pressure can precede a dementia diagnosis by approximately three years, highlighting its potential role as an early indicator of neurodegenerative processes.^[2] This association is further supported by findings that hypotensive individuals exhibit a significantly higher proportion of CI compared to their non-hypotensive counterparts.^[2]The underlying mechanisms linking hypotension to cognitive decline involve inadequate cerebral perfusion, loss of autoregulation, and endothelial dysfunction within the neurovascular unit, which can precipitate microvascular disease, stroke, and the deposition of amyloid-beta proteins and neurofibrillary tangles.^[2]Furthermore, the incidence of orthostatic hypotension is notably higher in Alzheimer’s disease patients, underscoring blood pressure dysregulation as a factor that may accelerate cognitive decline.^[2]Therefore, the diligent monitoring and comprehensive understanding of hypotension are crucial for predicting cognitive outcomes and recognizing its comorbidity with various forms of dementia in elderly patients.

Genetic Markers and Personalized Risk Stratification

The identification of specific genetic polymorphisms offers a crucial pathway for personalized risk stratification in hypotensive individuals, particularly concerning their susceptibility to cognitive impairment. A genome-wide association study conducted in an aging population identified several single nucleotide polymorphisms (SNPs) within theLRRTM4 gene (rs13388459 , rs1075716 , rs62171995 , rs17406146 , rs2077823 , rs62170897 ), the PCSK5 gene (rs10521467 ), and an intergenic region (rs117129097 ) that serve as markers for CI coexisting with hypotension.^[2]While most of these identified SNPs were not independently associated with CI or blood pressure regulation, they demonstrated a suggestive interaction effect with hypotension, significantly increasing the risk of CI.^[2] For instance, hypotensive subjects carrying the T allele of LRRTM4 rs13388459 showed a higher incidence of CI in an additive manner.^[2] Notably, the intergenic SNP rs117129097 was directly associated with hypotension, suggesting a potential genetic predisposition to low blood pressure itself.^[2]These findings imply that individuals carrying minor alleles of these specific SNPs, when also experiencing hypotension, are more susceptible to CI. This genetic insight can profoundly inform risk assessment, enabling the identification of high-risk individuals who may benefit from tailored prevention strategies and closer monitoring, thereby advancing personalized medicine approaches in managing hypotension-related cognitive risks.^[2]

Clinical Management and Monitoring Strategies

The clinical relevance of hypotension extends significantly into guiding treatment selection and developing effective monitoring strategies, particularly within vulnerable patient populations. Given the identified genetic predispositions, clinicians should exercise caution with intensive blood pressure lowering in elderly patients, especially those carrying minor alleles of the identifiedLRRTM4, PCSK5, and intergenic SNPs, to prevent potential treatment-induced neurodegeneration.^[2]The concept of a “J-curve” phenomenon underscores that both excessively low (e.g., DBP < 60 mmHg) and high blood pressure levels can correlate with adverse cardiovascular risks and accelerated cognitive decline, suggesting that maintaining an optimal, rather than simply lower, blood pressure range is crucial.^[2]For patients presenting with orthostatic hypotension, cognitive impairment, and multiple comorbidities, aggressive blood pressure reduction carries a heightened risk of adverse outcomes, making the precise optimal blood pressure target a subject of ongoing discussion in neurodegeneration.^[2]Therefore, comprehensive monitoring strategies that meticulously consider individual patient characteristics, including their genetic profiles and existing comorbidities, are essential. This nuanced approach enables clinicians to select appropriate treatment regimens, effectively balance the risks and benefits of blood pressure management, and implement proactive prevention strategies to mitigate the long-term cognitive implications of hypotension.

Frequently Asked Questions About Hypotension

These questions address the most important and specific aspects of hypotension based on current genetic research.

---

1. Why do I get dizzy when I stand up quickly, unlike others?

Yes, this is a common symptom of orthostatic hypotension. Your blood pressure is tightly regulated by your body, but genetic factors can influence how well your body adjusts to changes, like standing up. This can lead to insufficient blood flow to your brain, causing dizziness, while others might have different genetic predispositions that help them adjust better.

2. My mom faints; will I also struggle with low blood pressure?

It’s possible. Genetic factors are known to influence blood pressure variability and can predispose individuals to both high and low blood pressure. If your mom has hypotension, there’s a chance you might have inherited some of the genetic predispositions that contribute to it, but many factors are at play.

3. I’m a woman and thin; am I more likely to have low blood pressure?

Yes, studies have observed that individuals of female sex and those with a lower Body Mass Index (BMI) are more prone to hypotension. While genetics play a role in your overall body type and how your blood pressure is regulated, these demographic factors are also linked to a higher likelihood of experiencing low blood pressure.

4. Could my low blood pressure affect my memory as I get older?

Yes, research suggests a link between hypotension and cognitive impairment, especially in aging populations. For example, specific genetic variants in genes likeLRRTM4have been found to interact with hypotension, leading to a higher incidence of cognitive issues in hypotensive individuals carrying certain alleles as they age.

5. Why do I feel so tired all the time, even more than my friends?

Fatigue is a common symptom of hypotension, resulting from insufficient blood flow to vital organs. Your genetic makeup can influence your baseline blood pressure and how your body responds to it, meaning some individuals might be more susceptible to experiencing fatigue due to their genetic predisposition to lower blood pressure.

6. Does my ethnic background change my risk for low blood pressure?

Research on genetic markers for hypotension often faces limitations regarding generalizability across diverse populations due to ancestry bias. Many studies call for replication in different ethnic groups, suggesting that genetic risk factors and their prevalence might vary between backgrounds, making your ethnic background potentially relevant.

7. Can my diet or daily habits make my low blood pressure worse?

Environmental factors, including lifestyle and diet, can significantly influence blood pressure and interact with your genetic predispositions. While genetics set a baseline, what you eat and your daily habits can either exacerbate symptoms or help manage them, though detailed long-term dietary impacts are still being studied.

8. Why do some people always have low blood pressure, but feel fine?

Unlike hypertension, which is often asymptomatic, hypotension frequently presents with noticeable symptoms. However, some individuals might have blood pressure readings that are technically low but don’t experience symptoms because their bodies have adapted or their genetic makeup allows for better compensation, leading to sufficient blood flow despite the low numbers.

9. Is there a test to see if I’m genetically prone to low blood pressure?

While genetic factors are known to influence blood pressure, current research has identified a limited number of specific genetic variants associated with hypotension, such as in genes likeLRRTM4 and PCSK5. A comprehensive genetic risk score for hypotension isn’t widely available or fully developed yet due to the complexity and ongoing research.

10. I take other medications; could they affect my blood pressure?

Yes, medication use is a critical environmental factor that can influence blood pressure. The article notes that detailed medication lists are important for accurately studying genetic effects because pharmacological interventions can confound observed genetic associations. It’s possible your medications could be impacting your blood pressure.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Tobin, MD et al. “Common variants in genes underlying monogenic hypertension and hypotension and blood pressure in the general population.”Hypertension, vol. 51, 2008, pp. 1658–1664.

[2] Chen, Y. C. “LRRTM4 and PCSK5 Genetic Polymorphisms as Markers for Cognitive Impairment in A Hypotensive Aging Population: A Genome-Wide Association Study in Taiwan.”Journal of Clinical Medicine, vol. 8, no. 8, 2019, p. 1124.

[3] He, J, et al. “Genome-wide association study identifies 8 novel loci associated with blood pressure responses to interventions in Han Chinese.” Circ Cardiovasc Genet, vol. 6, no. 6, 2013, pp. 598–607.

[4] Vasan, R. S., et al. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.”BMC Medical Genetics, vol. 8, suppl. 1, 2007, S2.

[5] Jensen, R. A., et al. “Genome-wide association study of retinopathy in individuals without diabetes.”PLoS One, vol. 8, no. 2, 2013, e53211.

[6] Vukadinovic, M., et al. “Deep learning-enabled analysis of medical images identifies cardiac sphericity as an early marker of cardiomyopathy and related outcomes.”Med, vol. 4, no. 4, 2023, pp. 719-734.e5.

[7] Khurshid, S., et al. “Clinical and genetic associations of deep learning-derived cardiac magnetic resonance-based left ventricular mass.”Nature Communications, vol. 14, no. 1, 2023, p. 1599.

[8] Smith, J. G., et al. “Genome-wide association study of electrocardiographic conduction measures in an isolated founder population: Kosrae.” Heart Rhythm, vol. 6, no. 5, 2009, pp. 631-637.

[9] Sayeski, Peter P., and M. Showkat-Ali. “The critical role of c-Src and the Shc/Grb2/ERK2 signaling pathway in angiotensin II-dependent VSMC proliferation.” Experimental Cell Research, vol. 287, no. 2, 2003, pp. 339–349.

[10] Newton-Cheh, C et al. “Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure.” Nature Genetics, 2009.

[11] Vogel, V et al. “The renal endothelin system in the Prague hypertensive rat, a new model of spontaneous hypertension.”Clin Sci (Lond), 1999.

[12] Du, Y. H., et al. “Endothelium-specific GTP cyclohydrolase Ioverexpression attenuates blood pressure progression in salt-sensitive low-renin hypertension.”Circulation, vol. 117, no. 8, 2008, pp. 1045–54.

[13] Vargas, F., et al. “The renin-angiotensin system in thyroid disorders and its role in cardiovascular and renal manifestations.”Journal of Endocrinology, vol. 213, no. 1, 2012, pp. 25–36.

[14] Rodriguez-Iturbe, B et al. “Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all.”Am J Physiol Renal Physiol, 2004.

[15] Watanabe, M., et al. “Regulation of smooth muscle cell differentiation byAT-rich interaction domain transcription factors Mrf2alpha and Mrf2beta.” Circulation Research, vol. 91, no. 5, 2002, pp. 382–9.

[16] Postma, Arnt V., et al. “A gain-of-function TBX5 mutation is associated with atypical Holt-Oram syndrome and paroxysmal atrial fibrillation.” Circulation Research, vol. 102, no. 11, 2008, pp. 1433–42.

[17] Kardia, Sharon L. “Context-dependent genetic effects in hypertension.”Current Hypertension Reports, vol. 2, no. 1, 2000, pp. 32-38.

[18] Velazquez, L., et al. “Cytokine signaling and hematopoietic homeostasis are disrupted inLnk-deficient mice.” Journal of Experimental Medicine, vol. 195, no. 12, 2002, pp. 1599–611.